Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, ...
Delaying dupilumab initiation beyond 90 days after a severe asthma exacerbation was linked to a 32% increase in predicted ...
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on ...
A population-based cohort (1996–2021) of 2.94 million individuals assigned female at birth found endometriosis conferred ...
Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to ...
Prior authorization, fail-first step therapy, and market consolidation among pharmacy benefit managers (PBMs) are driving up ...
Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven ...
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on ...
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival ...
HFpEF/HFmrEF represent roughly 60% to 75% of US heart failure, and registries report >70% HFpEF, yet morbidity and mortality appear similar across ejection fraction categories.
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in. Obesity is diagnosed during hundreds of thousands, if not ...
Nicola A. Hanania, MD, MS, is an associate professor of medicine in the section of pulmonary and critical care medicine and director of the American Lung Association Airways Clinical Research Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results